BTS: Bacterial Transmission Dynamics Study

Sponsor
University of Oxford (Other)
Overall Status
Completed
CT.gov ID
NCT02401204
Collaborator
Mahidol Oxford Tropical Medicine Research Unit (Other), Queen Sirikit National Institute of Child Health (Other)
97
1
50.9
1.9

Study Details

Study Description

Brief Summary

Infections with multiply antibiotic-resistant bacteria represent a major cause of preventable morbidity and mortality amongst hospitalized neonates worldwide. In Southeast Asia, where antibiotic-resistance is a major problem, Gram-negative bacteria account for the majority of such infections. The most common pathogens are Acinetobacter spp., Pseudomonas aeruginosa, Enterobacter spp., Escherichia coli and Klebsiella pneumonia. The great majority of infections with these pathogens represent asymptomatic carriage, though in the absence of routine screening for asymptomatic carriage reliable estimates of the prevalence, rates of transmission between patients, and rates of importation from the community are lacking. Moreover, current understanding of the degree and manner in which different antibiotics act to select for such resistant organisms is rudimentary.

Condition or Disease Intervention/Treatment Phase
  • Other: Longitudinal surveillance study

Detailed Description

Objectives: To quantify the prevalence of drug-resistant Gram-negative pathogens on admission to a neonatal intensive care unit and during subsequent days of hospital stay. To quantify rates of patient-to-patient transmission for key organisms, to characterize how patient antibiotic use impacts on the ward-level dynamics of such organisms.

Methods: All infants admitted to the unit over a period of one year for whom the parent/guardian gives informed consent will be included. In addition to routine demographic and clinical data for included patients, full patient-level data on antibiotic use within the ward will also be recorded. Carriage of resistant Gram-negative organisms will be determined though rectal swabs, tracheal aspirates (for ventilated patients) and stool samples taken on admission and at twice weekly intervals. Antibiotic-resistant Gram-negative bacteria will be cultured and their resistant patterns determined. Selected environmental surfaces will also be sampled to detect contamination with such organisms. For the most important organisms (Acinetobacter spp. and Klebsiella spp.) whole genome sequencing will be used in conjunction with Bayesian data augmentation techniques to determine transmission pathways and the impact of antibiotic use on the transmission and persistence of such organisms within the hospital ward.

Study Design

Study Type:
Observational
Actual Enrollment :
97 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
Bacterial Transmission Surveillance in Neonatal Intensive Care Unit: Transmission Dynamics and Drug Resistance Patterns
Actual Study Start Date :
Feb 1, 2015
Actual Primary Completion Date :
May 1, 2019
Actual Study Completion Date :
May 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Neonates admitted to QSNICH NICU

All neonates admitted to the QSNICH NICU over a period of one year from March 2015 to March 2016 meeting the inclusion and exclusion criteria will be enrolled in the study. Readmitted neonates will be eligible to be enrolled again into the study.

Other: Longitudinal surveillance study
Regular specimens will be routinely collected as standard of practice. A rectal swab and stool specimen will be collected twice a week since first admission on NICU until discharge from NICU. If participant is intubated/ventilated, a throat swab will be collected.

Outcome Measures

Primary Outcome Measures

  1. Number of neonates who acquired infection from each expected pathogens during admission in NICU unit. [During admission in NICU unit]

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A to 1 Month
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • All neonates admitted to QSNICH NICU

  • Parent/legal guardian gives written informed consent

Exclusion Criteria:

• There are no exclusion criteria for this study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Queen Sirikit National Institute of Child Health Ratchathewi Bangkok Thailand 10400

Sponsors and Collaborators

  • University of Oxford
  • Mahidol Oxford Tropical Medicine Research Unit
  • Queen Sirikit National Institute of Child Health

Investigators

  • Principal Investigator: Ben Cooper, Dr., Mahidol Oxford Tropical Medicine Research Unit

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Oxford
ClinicalTrials.gov Identifier:
NCT02401204
Other Study ID Numbers:
  • MODEL1402
First Posted:
Mar 27, 2015
Last Update Posted:
Sep 11, 2019
Last Verified:
Sep 1, 2019
Keywords provided by University of Oxford

Study Results

No Results Posted as of Sep 11, 2019